

9. López Zúñiga MA, Martín Toro MA, de Damas Medina M. Datos de vida real en el uso de iPCSK9. *Rev Clin Esp (Barc)*. 2019;219:466–8.
10. Mathew RO, Rosenson RS, Lyubarova R, Chaudhry R, Costa SP, Bangalore S, et al. Concepts and controversies: lipid management in patients with chronic kidney disease. *Cardiovasc Drugs Ther*. 2021;35:479–89.

Verónica Escudero Quesada*, Jonay Pantoja Pérez, Cristina Castro Alonso, July Vanessa Osma Capera, Alejandro Valero Antón, Asunción Sancho Calabuig

Servicio de Nefrología, Hospital Universitario Dr. Peset, Valencia, Spain

*Corresponding author.

E-mail address: veesque@gmail.com (V. Escudero Quesada).

2013-2514/© 2024 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Nefrología. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>). <https://doi.org/10.1016/j.nefro.2024.02.007>



Acute kidney injury (AKI): Spanish nomenclature also matters here

AKI (Acute Kidney Injury): AQUÍ la nomenclatura también es importante

Dear Editor,

We recently led a multinational initiative to standardise our nephrology nomenclature in Spanish,¹ following the Kidney Disease Initiative Global Outcomes (KDIGO) Consensus Conference on Kidney Function and Disease Nomenclature.² Among other aspects, we also highlighted the existence of a certain discrimination of classical terminology of Latin origin, such as the adjective “renal”.³ It was also of great interest that the “Registro Latinoamericano de Diálisis y Trasplante Renal” [Latin American Registry of Dialysis and Renal Transplantation] and the Acute Kidney Injury Committee of the Sociedad Latinoamericana de Nefrología e Hipertensión (SLANH) [Latin American Society of Nephrology and Hypertension] also published a proposal for an Ibero-American consensus on nomenclature harmonisation.⁴

In the aforementioned initiative,¹ which is primarily focused on concepts essentially oriented towards chronic kidney disease (CKD), we have already pointed out that the introduction of new Anglo-Saxon terminology such as Acute Kidney Injury (AKI) has led to a clear dispersion in Spanish (from fallo or falla; alteración; fracaso; insuficiencia; daño; lesión or even injuria—an obvious anglicism).⁵ The term fallo renal or falla renal (for the English failure) contains contradictions in the KDIGO and SLANH guidelines’ own definitions (in one defined simply as duration of renal disease > three months and in the other as equivalent to “fracaso” renal” or CKD G5 (with or without renal replacement therapy).^{2,4} We had already emphasised that “fracaso” renal agudo (FRA), according to the KDIGO guidelines,⁶ would be equivalent to AKI stage 3, so that the Spanish terms daño, injuria, lesión, fallo (o falla) renal agudo would not necessarily mean “fracaso” renal. It was also suggested that “daño renal” or “injuria renal” should not be

used (despite the names used by some committees) for various reasons, ranging from a lack of tradition to the fact that the term AKI is a purely cosmetic change, still defined by imprecise renal function and not by objective, function-independent markers of structural damage. It is also worth noting the introduction of the international concept of acute kidney disease (AKD) (decline in renal function more than seven days and less than three months), which refers by consensus to the transition after an acute episode towards the established criteria of CKD (Table 1).

Therefore, we understand that the conceptual evolution of the current model of acute kidney injury (AKI) (Fig. 1) has not only allowed new definitions to be introduced into the nomenclature, but has also broadened our knowledge of new mechanisms of kidney injury, which is why we believe that the early homogenisation of the terms disfunción, lesión, fracaso renal agudo is essential.

This urgent call for attention is also linked to the existence of the “Acute Renal Failure” group of the Sociedad Española de Nefrología [Spanish Society of Nephrology], which has recently been interested (among other issues) in better understanding the role of nephrology in the management of kidney replacement therapies in intensive care units, but which should also take into account terminologically the broader and earlier concept of AKI. In fact, both patients with acute kidney function impairment [AKI 1-3 or “FRA” (AKI 3)] and AKI, as well as patients with impaired renal function without structural damage (pseudo worsening renal function” or “permissive AKI; in Anglo-Saxon terminology) are possible.^{7,8} Therefore, and in order to respect widely used terms, we would like to stress that the term fracaso renal agudo and its acronym FRA should be reserved only for patients with KDIGO criteria (AKI 3). Given that creatinine is the only widely available biomarker, the term insuficiencia renal aguda (IRA [acute renal insufficiency], in its different stages 1-2-3, based on the inter-

Table 1 – Accepted terminology for the timing and severity of the acute kidney injury (AKI), chronic kidney disease (CKD) continuum. The term acute kidney insufficiency would be a term which, although old, would encompass both the also proposed concept of impairment of renal function and the different stages of severity. The grading of severity could also be called an estadio(stage) as the Real Academia Española (RAE) [Royal Spanish Academy that publishes the Spanish dictionary] describes it as the period or phase of a process:

Accepted terminology				
	Acute kidney injury	Acute kidney disease	Renal recovery	Chronic kidney disease
Time since onset	<7 days ^a	≥7 days ^a	Early recovery (<7 days) ^b Late recovery (≥7 days) ^b	≥3 months ^a
Severity	Grade 1 Grade 2 Grade 3	Grade 1 Grade 2 Grade 3	Grade 3 Grade 2 Grade 1	Grade 1 Grade 2 Grade 3a and 3b Grade 4 Grade 5

^a Adapted from Refs. 2 and 6.
^b Adapted from Ref. 10.




Figure 1 – Evolving of the conceptual model of acute kidney injury (AKI): from clinical to molecular diagnosis. ADQI: Acute Disease Quality Initiative; AKD: acute kidney disease; AKI: Acute kidney injury; AKIN: Acute Kidney Injury Network; KDIGO: Kidney Disease Improving Global Outcomes.

national KDIGO classification)⁶ would be a term that, although old, would encompass both the concept of impairment of renal function and the different stages of severity. However, the acronym IRA could be confused with insuficiencia respiratoria aguda [acute respiratory insufficiency]. The term IRA ([lesión renal aguda] acute kidney injury; AKI) is increasingly used because it is known that structural damage precedes functional impairment (subclinical AKI, renal angina or acute kidney stress).⁹

Finally, as we have already mentioned,¹ it is important to highlight that this dispersion (or, on the contrary, homogenisation) in the nomenclature takes on great relevance today when we think about the efficiency, not only of our literature searches, but, more importantly, when we anticipate and think about the use of the new tools of Artificial Intelligence/Machine-Learning and the exploitation of Big-Data in this context. In addition, we should already be

working on increasing the importance of nomenclature, not only in terms of defining AKI, but also in terms of properly agreeing concepts for "recuperación renal [renal recovery] based on decreasing severity or speed of recovery, with assistance and epidemiological objectives in mind, even taking into account that a decrease in creatinine to baseline values does not always mean complete return to normal.¹⁰

Conflicts of interest

The authors have no conflicts of interest.

REFERENCES

1. Bover J, Bosch R, Górriz JL, Ureña P, Ortiz A, daSilva I, et al. Los riñones también hablan español: iniciativas hacia la

- estandarización de nuestra nomenclatura nefrológica. *Nefrología*. 2022;42:223–32, <http://dx.doi.org/10.1016/J.NEFRO.2021.04.011>.
2. Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR, et al. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. *Kidney Int*. 2020;97:1117–29, <http://dx.doi.org/10.1016/J.KINT.2020.02.010/ATTACHMENT/21691997-06D2-432C-AAD2-DAB51425F000/MMC1.PDF>.
 3. Bover J, Haarhaus ML, Furlano M, Ureña P, Vervloet M, daSilva I, et al. English–Latin nomenclature conundrum: should we use kidneylogy, kidneylogist? *Kidney Int*. 2020;98:1352–3, <http://dx.doi.org/10.1016/J.KINT.2020.08.015>.
 4. Ferreiro-Fuentes A, González-Bedat MC, Lombardi R, Lugon J, Mastroianni G, Mira F, et al. Consenso iberoamericano para uniformar la nomenclatura de la función y las enfermedades renales. *Nefrol Latinoam*. 2020;17, <http://dx.doi.org/10.24875/NEFRO.M20000009>.
 5. Liaño F, Candela A, Tenorio MT, Rodríguez-Palomares JR. La IRA en la UCI: Concepto, clasificaciones funcionales, epidemiología, biomarcadores, diagnóstico diferencial y pronóstico. In: *Manejo de la disfunción aguda del riñón del paciente crítico en la práctica clínica*. 1st ed. Madrid, Spain: Ergon; 2011. p. 1–21.
 6. Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, et al. KDIGO clinical practice guideline for acute kidney injury. *Kidney Int Suppl*. 2012;2:1–138, <http://dx.doi.org/10.1038/KISUP.2012.1>.
 7. Mullens W, Martens P, Testani JM, Wilson Tang WH, Skouri H, Verbrugge FH, et al. Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail*. 2022;24:603–19, <http://dx.doi.org/10.1002/EJHF.2471>.
 8. Parikh CR, Coca SG. “Permissive AKI” with treatment of heart failure. *Kidney Int*. 2019;96:1066–8, <http://dx.doi.org/10.1016/J.KINT.2019.07.003>.
 9. Ronco C, Kellum JA, Haase M. Subclinical AKI is still AKI. *Critical Care*. 2012;16:1–4, <http://dx.doi.org/10.1186/CC11240/TABLES/1>.
 10. Chawla LS, Bellomo R, Bihorac A, Goldstein SL, Siew ED, Bagshaw SM, et al. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. *Nat Rev Nephrol*. 2017;13:241–57, <http://dx.doi.org/10.1038/nrneph.2017.2>.
- Jordi Bover ^{a,b,*}, Gregorio Romero-González ^{a,b,c}, Jonathan Samuel Chávez-Iñiguez ^{d,e}, Lilia Rizo-Topete ^{c,f,g}, Fredzzia Graterol ^{a,b}, Anna Vila Santandreu ^{a,b}, Maya Sanchez-Baya ^{a,b}, Joan Manel Díaz ^h, Alberto Ortiz ⁱ, Esteban Poch ^j
- ^a Nephrology Department, University Hospital Germans Trias i Pujol, Badalona, Spain
^b Germans Trias i Pujol Research Institute (IGTP), REMAR- IGTP Group (Kidney-affecting Diseases Research Group), Badalona, Spain
^c International Renal Research Institute of Vicenza, Vicenza, Italy
^d Nephrology Department, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico
^e Universidad de Guadalajara, Centro Universitario de Ciencias de la salud CUCS, Guadalajara, Jalisco, Mexico
^f UANL, Hospital Universitario “José Eleuterio González”, Monterrey, Nuevo León, Mexico
^g Hospital Christus Muguerza Alta Especialidad, UDEM, Monterrey, Nuevo León, Mexico
^h Nephrology Department, Fundació Puigvert, Hospital Santa Cruz y San Pablo, Barcelona, Spain
ⁱ Nephrology Department, Fundación Jiménez Díaz, Madrid, Spain
^j Nephrology Department, Hospital Clínic, Barcelona, Spain
- *Corresponding author.
 E-mail address: jbover.ics@gencat.cat (J. Bover).
- 2013-2514/© 2024 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Nefrología. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).
<https://doi.org/10.1016/j.nefro.2024.02.009>

I'm a Nephrologist and I give urea to my patients. SIAD in oncological patients

Soy nefrólogo y trato a mis pacientes con urea. SIAD en pacientes oncológicos

Dear Editor:

Syndrome of inappropriate antidiuresis (SIAD) is an emerging problem in cancer patients and is responsible for one-third of cancer-related hyponatremia. SIAD can cause reduced quality of life, longer hospital admissions, and increased costs.¹

DOI of original article:
<https://doi.org/10.1016/j.nefro.2022.07.003>.

Fluid restriction (FR) and increasing renal free water excretion are the basis of chronic cancer-related hyponatremia treatment. International guidelines put loop diuretics, urea, vaptans, or demeclocycline after FR, as first-line treatments.^{2,3}

Urea had increased interest in the last years due to its effectiveness, and good safety profile.⁴ We hypothesized that urea is a good option in the treatment of SIAD in cancer patients.

We enrolled 11 cancer patients who were diagnosed with SIAD, from August 2021 until March 2022, that were treated

